The Substance P Receptor pipeline drugs market research report outlays comprehensive information on the Substance P Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Substance P Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Toxicology, Central Nervous System, Infectious Disease, and Oncology which include the indications Chemotherapy Induced Nausea and Vomiting, Pulmonary Radiation Toxicity , Traumatic Brain Injury, Intracranial Hypertension, Bacterial Infections, Influenza A Virus, H1N1 Subtype Infections, Metastatic Melanoma, and Non-Small Cell Lung Cancer. It also reviews key players involved in Substance P Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Substance P Receptor pipeline targets constitutes close to 25 molecules. Out of which, approximately 23 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 3, 1, 6, 2, 7, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Substance P Receptor overview
Substance P (SP) is a neuropeptide that is released from sensory nerve endings. It is an 11 amino acid neuropeptide that belongs to the tachykinin family. It acts on bones and related tissues by binding to receptors, thereby regulating bone metabolism, cartilage metabolism, and fracture healing. SP’s biological actions are mediated by three subtypes of neurokinin receptors (NK1, NK2, and NK3). The most abundant subtype in the CNS is NK1, which is present in the hippocampus, hypothalamus, and amygdala.
For a complete picture of Substance P Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
